The first major publication describing the PROTAC® technology is published by Arvinas founder, Craig Crews, and team.
Arvinas is founded, leading the way in turning targeted protein degraders into treatments for patients.
Arvinas announces partnership with Genentech (later expanded in 2017).
Arvinas first creates orally bioavailable PROTAC protein degraders.
Arvinas announces partnership with Pfizer.
Arvinas first creates PROTAC protein degraders that cross the blood-brain barrier.
Arvinas prices initial public offering of stock (Nasdaq:ARVN).
Arvinas begins first ever clinical study of a targeted protein degrader: ARV-110 for the potential treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Arvinas announces a partnership with Bayer, including a pharmaceutical collaboration and the launch of an agricultural joint venture, Oerth Bio.
Arvinas announces that its second targeted protein degrader has entered the clinic: ARV-471 for the potential treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
Arvinas announces initial safety and pharmacokinetic data for its first clinical programs, ARV-110 and ARV-471.
Arvinas releases clinical data demonstrating efficacy proof-of-concept for PROTAC protein degraders ARV-471 and ARV-110
Arvinas begins the ARDENT Phase 2 expansion cohort for ARV-110
Arvinas begins the VERITAC Phase 2 expansion cohort for ARV-471
Arvinas announces global collaboration with Pfizer to co-develop and co-commercialize ARV-471